Clozapine N-oxide
 | |
| Names | |
|---|---|
| IUPAC name 3-chloro-6-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-11H-benzo[b][1,4]benzodiazepine | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.164.243 |
PubChem CID | |
| UNII | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C18H19ClN4O | |
| Molar mass | 342.83 g·mol−1 |
| Hazards | |
| GHS labelling: | |
  | |
| Danger | |
| H301, H315, H319, H335 | |
| P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 | This article may be too technical for most readers to understand. (March 2021) |
Clozapine N-oxide (CNO) is a synthetic drug used mainly in biomedical research as a ligand to activate Designer Receptors Exclusively Activated by Designer Drugs (DREADDs),[1] despite the initial belief that it was biologically inert. However, it has been shown to not enter the brain after administration[2] and to reverse metabolize in peripheral tissues to form clozapine. Clozapine can bind to a number of different serotonergic, dopaminergic and adrenergic receptors within the brain.[3] These off-target effects mean behavioral data using the CNO-DREADD system have to be interpreted with caution.[4]
Alternatives to CNO with more affinity, more inert character, and faster kinetics include Compound 21 (C21)[5] and deschloroclozapine (DCZ).[6]
References
[edit]- ^ Armbruster, B. N.; Li, X.; Pausch, M. H.; Herlitze, S.; Roth, B. L. (2007-03-02). "Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand". Proceedings of the National Academy of Sciences. 104 (12): 5163–5168. Bibcode:2007PNAS..104.5163A. doi:10.1073/pnas.0700293104. ISSN 0027-8424. PMC 1829280. PMID 17360345.
- ^ Gomez, Juan L.; Bonaventura, Jordi; Lesniak, Wojciech; Mathews, William B.; Sysa-Shah, Polina; Rodriguez, Lionel A.; Ellis, Randall J.; Richie, Christopher T.; Harvey, Brandon K.; Dannals, Robert F.; Pomper, Martin G. (2017-08-04). "Chemogenetics revealed: DREADD occupancy and activation via converted clozapine". Science. 357 (6350): 503–507. Bibcode:2017Sci...357..503G. doi:10.1126/science.aan2475. ISSN 1095-9203. PMC 7309169. PMID 28774929.
- ^ Manvich, Daniel F.; Webster, Kevin A.; Foster, Stephanie L.; Farrell, Martilias S.; Ritchie, James C.; Porter, Joseph H.; Weinshenker, David (2018-03-01). "The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice". Scientific Reports. 8 (1): 3840. Bibcode:2018NatSR...8.3840M. doi:10.1038/s41598-018-22116-z. ISSN 2045-2322. PMC 5832819. PMID 29497149.
- ^
This article incorporates text available under the CC BY 4.0 license. Ju, William (November 1, 2023). Neuroscience. Toronto: University of Toronto. 3.4 Chemogenic methods to examine the brain behaviour. - ^ Bonaventura, Jordi; Eldridge, Mark A. G.; Hu, Feng; Gomez, Juan L.; Sanchez-Soto, Marta; Abramyan, Ara M.; Lam, Sherry; Boehm, Matthew A.; Ruiz, Christina; Farrell, Mitchell R.; Moreno, Andrea (2019-10-11). "High-potency ligands for DREADD imaging and activation in rodents and monkeys". Nature Communications. 10 (1): 4627. Bibcode:2019NatCo..10.4627B. doi:10.1038/s41467-019-12236-z. ISSN 2041-1723. PMC 6788984. PMID 31604917.
- ^ Nagai, Yuji; Miyakawa, Naohisa; Takuwa, Hiroyuki; Hori, Yukiko; Oyama, Kei; Ji, Bin; Takahashi, Manami; Huang, Xi-Ping; Slocum, Samuel T.; DiBerto, Jeffrey F.; Xiong, Yan (September 2020). "Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys". Nature Neuroscience. 23 (9): 1157–1167. doi:10.1038/s41593-020-0661-3. ISSN 1546-1726. PMID 32632286. S2CID 220375204.
